Novartis lung cancer drug gets EU recommendation

LONDON, Feb 27 (Reuters) - European health regulators said on Friday they had recommended approval of a drug for advanced lung cancer developed by Swiss drugmaker Novartis that is intended to treat patients with a specific genetic mutation.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.